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1Cardiac resynchronization therapy (CRT) has been dem-onstrated to reduce morbidity and mortality in numer-
ous large clinical trials, and it has become an integral part of 
contemporary heart failure therapy.1–3 The inclusion criteria of 
these trials form the basis of current guidelines, recommend-
ing CRT for patients with a severely reduced left ventricular 
ejection fraction of ≤35%, symptomatic chronic heart failure 
(CHF), and a QRS complex of ≥120 ms.4 Because the major-
ity of patients with CHF present with a narrow QRS complex,5 
the EchoCRT trial was designed to investigate the effect of 
CRT in patients with a QRS duration of <130 ms together with 
echocardiographic evidence of left ventricular dyssynchrony.6 
The trial was terminated early because of futility, but also 
indicated an increased risk for all-cause mortality of 81% with 
CRT in this patient population. The sex distribution, as well 
as the reason for the overall increase in mortality observed in 
Echo CRT is presently still unclear.
Sex-specific results of CRT have been suggested by 
some, but not all, previous studies. For example, the Cardiac 
Resynchronization–Heart Failure (CARE-HF) study1 was 
unable to find a sex-by-treatment interaction, whereas in 
MADIT (Multicenter Automatic Defibrillator Implantation)-
CRT, women experienced a 79% reduction in the primary end 
point (death or heart failure) when compared with only 28% 
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Original Article
Background—In EchoCRT, a randomized controlled trial evaluating the effect of cardiac resynchronization therapy (CRT) 
in patients with a QRS duration of <130 ms and echocardiographic evidence of left ventricular dyssynchrony, the primary 
outcome (death from any cause or first hospitalization for worsening heart failure) occurred more frequently in the CRT-
ON when compared with the control group. In this prespecified subgroup analysis, we evaluated the effect of sex on 
clinical outcome in EchoCRT.
Methods and Results—In EchoCRT, 585 (72%) of included patients were men. At baseline, male patients had a higher 
incidence of ischemic cardiomyopathy and longer QRS duration. On uni- and multivariable analysis, no significant 
interaction was observed regarding sex for the primary or any of the secondary end points. Numerically, a higher all-
cause mortality was observed in male patients randomized to CRT-ON versus CRT-OFF on univariable analysis (hazard 
ratio, 1.83; 95% confidence interval, 1.08–3.12); however, no statistically significant interaction compared with females 
randomized to CRT-ON versus CRT-OFF was noted (hazard ratio, 0.99; P interaction, 0.56). There was no difference in 
the primary safety end point of system-related complications, including CRT system- and implantation-related events.
Conclusions—The largest hazard for all-cause mortality in EchoCRT was observed in men randomized to CRT-ON; the 
comparison with women did not reach statistical significance, which may be because of the premature termination of the 
trial and the limited data. These results suggest that male sex may be a risk factor for harm by CRT in patients with narrow 
QRS width, an observation which deserves further investigation.
Clinical Trial Registration—URL: https://clinicaltrials.gov. Unique identifier: NCT00683696.   
(Circ Arrhythm Electrophysiol. 2016;9:e003924. DOI: 10.1161/CIRCEP.115.003924.)
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in men. More recently, pronounced female advantage for CRT 
effect was seen at shorter (120–150 ms) QRS durations.7,8
Whether the lack of benefit for CRT shown in EchoCRT 
pertains to all patients, or whether male or female patients with 
a narrow QRS complex and echocardiographic signs of dys-
synchrony may derive a benefit (or particularly pronounced 
harm) from CRT is presently unclear. The current prespeci-
fied subgroup analysis was, therefore, performed to assess the 
effect of sex on clinical outcome in EchoCRT.
Methods
Study Design and Conduct
The EchoCRT study was an investigator-initiated, international, 
multicenter, randomized clinical trial. The outcome results of the 
main trial, as well as the methodology have previously been report-
ed.6 In brief, the trial (sponsored by Biotronik) was designed by the 
executive committee with support for echocardiographic training 
and software provided by GE Healthcare. All study results were 
independently analyzed at the Robertson Center for Biostatistics 
at the University of Glasgow. Patients were eligible if they had 
New York Heart Association class III or IV heart failure, a left ven-
tricular ejection fraction of ≤35%, a standard indication for an im-
plantable cardioverter–defibrillator (ICD), optimized medical heart 
failure therapy, a QRS duration of less than 130 ms, a left ven-
tricular end-diastolic diameter of ≥55 mm, and echocardiographic 
evidence of left ventricular dyssynchrony as previously defined.6 
After implantation of a Biotronik Lumax HF-T CRT-D system, pa-
tients were randomly assigned in a 1:1 ratio to have CRT capability 
turned on (the CRT group) or to have CRT capability turned off 
(the control group). Device-implanting physicians were aware of 
the study-group assignments, but the patients, heart failure physi-
cians, and study personnel completing the follow-up assessments 
were unaware of the group assignments. The trial protocol was ap-
proved by the institutional review board at each participating cen-
ter, and all subjects provided written informed consent.
End Points
The primary efficacy outcome was the combination of death from 
any cause or first hospitalization for worsening heart failure.6 The 
prespecified secondary outcomes included all hospitalizations for 
worsening heart failure throughout the study: all-cause mortality, 
cardiovascular mortality, heart failure mortality, and cardiovascular 
hospitalization.6 The primary safety outcome was freedom from CRT-
D–related complications at 6 months in the implanted population. 
Complications were defined as adverse events that require additional 
invasive intervention to resolve, related to the implanted CRT system, 
including the device and leads. In addition, system-related complica-
tions during the whole trial were analyzed by treatment group.
Statistical Analysis
All analyses were performed according to the intention-to-treat prin-
ciple. Baseline characteristics were compared with the use of 2-sam-
ple t tests and χ2 (or Fisher exact) tests for continuous and categorical 
variables, respectively.
Hazard ratios (HRs) for CRT-ON and CRT-OFF with 95% confi-
dence intervals (CIs) were calculated with the Cox proportional haz-
ards models for male versus female patients, including the stratification 
factor of country in the model. In addition, a multivariable Cox propor-
tional hazards model was performed to account for differences across 
randomized treatment groups in baseline characteristics between males 
and females (QRS width, walking distance, quality of life [QOL] as 
determined by the Minnesota Living With Heart Failure Questionnaire 
score, sitting diastolic blood pressure, ischemic cardiomyopathy, his-
tory of myocardial infarction, history of coronary artery bypass graft-
ing, left ventricular end-diastolic diameter, and diuretic agent use). 
Interactions between males and females and treatment (CRT=ON and 
CRT=OFF) were tested for in Cox models that included sex and treat-
ment main effects and interaction terms. Time-to-event curves were 
estimated with the use of the Kaplan–Meier method. All tests were 2 
sided with a P value of <0.05 considered to be significant. Analyses 
were performed using SAS for Windows version 9.2.
Results
Baseline Characteristics
Metrics at trial entry are summarized in Table 1. Of 809 ran-
domized patients, 224 (27.7%) were females. Male patients 
had longer QRS complex duration, longer walking distance, 
slightly higher diastolic blood pressure, larger LV diameters, 
and more frequently had ischemic cardiomyopathy or related 
interventions. In contrast, women had worse heart failure 
related quality of life (QOL) and higher use of diuretics. Other 
baseline parameters were comparable among the 2 groups.
Efficacy of CRT in Male Versus Female Patients
There was no difference for male versus female patients regard-
ing the overall results of the trial, both unadjusted (Figures 1 
and 2) and after multivariable adjustment for differences in 
baseline characteristics as outlined above (ie, QRS width, 
walking distance, QOL score, sitting diastolic blood pressure, 
ischemic cardiomyopathy, history of myocardial infarction, 
history of CABG, left ventricular end-diastolic diameter, and 
diuretic agent use; Figure 3). Numerically, however, both the 
increased hazard of CRT for the primary end point, and espe-
cially the mortality end points, seemed to be driven mainly by 
an increased hazard in male patients. Strikingly, cardiovascu-
lar mortality was increased 2.4-fold in male patients (HR, 2.43 
[95% CI, 1.27–4.63]; P=0.007 versus HR, 0.97 [95% CI, 0.24–
3.93], P=0.97 for the females), albeit with a nonsignificant 
interaction P value. These observations were paralleled in the 
Kaplan–Meier analyses and in the multivariable adjusted model 
(again, however, without significant interaction).
WHAT IS KNOWN
•	The EchoCRT trial investigated the effect of CRT in 
patients with a QRS duration <130 ms and echocar-
diographic evidence of left ventricular dyssynchro-
ny. It was prematurely terminated due to futility, and 
it indicated an increased risk for all-cause mortality 
of 81% with CRT in this patient population.
•	Gender-specific responses to CRT have been sug-
gested by some, but not all, prior studies.
WHAT THE STUDY ADDS
•	The largest hazard for all-cause mortality in EchoCRT 
was observed in men randomized to CRT-ON.
•	The comparison with women did not reach statisti-
cal significance, which may be due to the premature 
termination of the trial.
•	These results suggest that male sex may be a risk fac-
tor for harm by CRT in patients with a narrow QRS 
width.
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Table 1. Baseline Characteristics
Variable Females Males P Value
Age, y 57.5 (13.62) 58.2 (12.38) 0.482
QRS width (ms; site) 102.4 (12.89) 106.3 (12.70) <0.001
QRS width (ms; core) 102.3 (13.35) 107.1 (12.01) <0.001
Walking distance (m) 286.7 (120.64) 340.4 (116.84) <0.001
Quality of life score 54.4 (24.15) 50.0 (24.21) 0.021
NYHA classification
  I 0 (0.00%) 5 (0.85%) *
  II 3 (1.34%) 16 (2.74%)
  III 213 (95.09%) 546 (93.33%)
  IV 8 (3.57%) 18 (3.08%)
BNP (pg/mL) 225.0 (102.00, 471.00) 251.0 (75.00, 515.00) 0.927
NT-proBNP (pg/mL) 1275.0 (610.00, 2124.0) 1095.5 (449.50, 2408.5) 0.604
Sitting SBP (mm Hg) 117.6 (18.11) 119.3 (19.87) 0.271
Sitting DBP (mm Hg) 71.4 (11.18) 73.3 (12.20) 0.039
BMI, kg/m2 31.7 (14.80) 30.5 (10.98) 0.212
Ischemic cardiomyopathy 88 (39.29%) 344 (58.90%) <0.001
MI >3 mo ago 66 (29.46%) 256 (43.76%) <0.001
PCI >3 mo ago 70 (31.25%) 218 (37.26%) 0.110
CABG >3 mo ago 23 (10.27%) 128 (21.88%) <0.001
Hypertension 146 (66.06%) 387 (66.61%) 0.884
Congenital heart disease 2 (0.92%) 14 (2.42%) 0.259
Previous ischemic stroke or TIA 27 (12.22%) 69 (11.86%) 0.888
Diabetes mellitus 95 (42.79%) 225 (38.53%) 0.269
Chronic lung disease 40 (18.02%) 109 (18.79%) 0.801
Chronic kidney disease 22 (9.95%) 86 (14.78%) 0.074
LVEF biplane (%) 27.2 (5.39) 26.9 (5.63) 0.477
LV end-diastolic diameter (mm) 64.1 (6.84) 67.3 (7.62) <0.001
Qualified by Tissue Doppler Imaging and radial dyssynchrony
  Tissue Doppler Imaging only 50 (22.32%) 152 (26.03%)
0.050  Radial strain only 42 (18.75%) 143 (24.49%)
  TDI and radial strain 132 (58.93%) 289 (49.49%)
Medication at study entry
  ACE inhibitor or ARB 212 (94.64%) 555 (94.87%) 0.896
  Aldosterone antagonist 130 (58.04%) 355 (60.68%) 0.492
  β-Blocker 216 (96.43%) 566 (96.75%) 0.828
  Diuretic agent 206 (91.96%) 492 (84.10%) 0.004
For categorical variables, number and percentage are reported; for continuous variables, mean and SD are reported 
(except for BNP and NT-proBNP where median and interquartile range are presented). ACE indicates angiotensin-
converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; DBP diastolic blood pressure; LVEF, left 
ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro b-type natriuretic peptide; NYHA, 
New York Heart Association; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; and SBP, systolic 
blood pressure.
*P value not reported because of small numbers.
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Device-Related Complications in Male Versus 
Female Patients
The primary safety end point (freedom from device-related 
complications at 6 months) in the implanted population 
(237 females and 618 males) is presented in Table 2. There 
were no differences in the primary safety end point, includ-
ing CRT system- and implantation-related events. Device-
related complications occurring during the whole trial in 
male and female patients are summarized in Table 3. The 
rate of ICD lead–related complications was numerically 
higher in women in the CRT-ON group, which was coun-
terbalanced by a numerically lower rate of ICD lead com-
plications in the CRT-OFF group in women (both when 
compared with men). Overall, the difference between ICD 
lead–related complications was similar and did not reach 
statistical significance.
Discussion
In the current prespecified subgroup analysis, a trend indicat-
ing a worse outcome for males compared with females can be 
observed. Indeed, on Kaplan–Meier analysis, the event curve 
for CRT-ON in women is almost a perfect match to that of 
CRT-OFF in women as well as in men, possibly indicating a 
balanced effect (ie, harm in some neutralized by benefit in oth-
ers). In contrast, male patients seem to be the main driver of 
worse outcomes of CRT-ON for the entire EchoCRT cohort. 
The lack of statistical significance may be because of the fact 
that the trial was prematurely terminated, resulting in a lack 
of statistical power both for the primary and for the secondary 
end points, which becomes even more relevant in subgroup 
analyses. It is tempting to speculate that had the trial been ter-
minated as planned, a statistically significant interaction may 
have been observed.
Figure 1. Kaplan–Meier estimates for primary-outcome events, stratified by sex. Kaplan–Meier curves for the primary composite efficacy 
outcome of death from any cause or hospitalization for heart failure (A), as well as the secondary end point all-cause mortality (B) and 
hospitalization for heart failure (C) in patients randomized to cardiac resynchronization therapy (CRT)-ON and CRT-OFF, stratified by sex.
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Our results indicating potential sex-specific differences 
in CRT effect are consistent with several other large out-
come studies, extending those observations to the narrow 
QRS range studied here. In the early Multicenter InSync 
Randomized Clinical Evaluation (MIRACLE) Study, women, 
but not men, receiving CRT had a longer time to first hospi-
talization for CHF as well as time to first CHF hospitaliza-
tion or death.9 In MADIT-CRT, female patients randomized 
to CRT treatment had a 69% relative risk reduction to experi-
ence the primary end point of death or heart failure versus 
ICD when compared with men, who only had 28% relative 
risk reduction (P interaction <0.001). This effect was driven 
both by a significant reduction in heart failure hospitalization 
(70% versus 35% risk reduction) and a significant reduction 
in all-cause mortality. Indeed, a reduction in all-cause mor-
tality was primarily evident in women (HR, 0.28; 95% CI, 
0.10–0.79), but not in men (HR, 1.05; 95% CI, 0.70–1.57; 
P interaction=0.03). A similar trend was also observed in 
the Resynchronization–Defibrillation for Ambulatory Heart 
Failure Trial (RAFT), the other large study investigating CRT 
in oligosymptomatic patients (P interaction=0.09).10 Finally, 
a large single-center CRT registry found a significant 56% 
Figure 2. Effect of cardiac resynchronization therapy (CRT) in female (top, black) and male (bottom, red) patients. Hazard ratio (HR; 95% 
confidence interval [CI]) adjusted for country and P value from Wald test are presented. WHF indicates worsening heart failure.
Figure 3. Effect of cardiac resynchronization therapy (CRT) in female (top, black) and male (bottom, red) patients after multivariable 
adjustment. Hazard ratio (HR; 95% confidence interval [CI]) adjusted for country, QRS width, walking distance, quality of life score, sitting 
diastolic blood pressure, ischemic cardiomyopathy, history of myocardial infarction, history of coronary artery bypass graft, left ventricular 
end-diastolic diameter, and diuretic agent use (P value from Wald test). WHF indicates worsening heart failure.
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lower all-cause mortality in women compared with men on 
multivariable analysis.11 When considered against QRS dura-
tion, female advantage (relative to male patients) was most 
pronounced at shorter (<150 ms) QRS durations.7 In contrast, 
some other studies have failed to demonstrate a significant 
difference between men and women, including CARE-HF.1 
Similarly in the Comparison of Medical Therapy, Pacing, and 
Defibrillation in Heart Failure (COMPANION) trial, no inter-
action by sex was observed, although women did have a lower 
hazard for sudden cardiac death or appropriate shocks.3,12
The reason for these differences is just as elusive as 
the mechanism underlying a potentially more pronounced 
benefit of CRT in women. Several explanations have been 
brought forward, including a higher proportion of ischemic 
cardiomyopathies as well as larger LV diameters in males. 
Indeed, the latter may play an important role, consistent with 
a point of no return in the natural course of CHF after which 
reverse LV remodeling —and, as a consequence, response to 
CRT—becomes less likely.13–15 Another hypothesis is related 
to the difference in QRS duration between men and women. 
Indeed, in healthy women (as well as in EchoCRT), the QRS 
duration is on average 4 to 10 ms shorter than that in male 
patients.16,17 As a result, male patients with a prolonged QRS 
complex may have relatively less electric dyssynchrony and 
intracardiac conduction disturbance for any given absolute 
QRS duration when compared with women, which may 
explain the more favorable outcome of CRT in females. 
Possibly, in shorter QRS ranges as examined here, there is 
little if any dyssynchrony among males.18 For these patients, 
ventricular stimulation itself may be associated with a worse 
outcome, similar to the development of pacemaker-mediated 
cardiomyopathy.19 Indeed, separation of the Kaplan–Meier 
curve for CRT-ON in males mostly occurs 1.5 to 2 years 
after implantation, which may indicate a detrimental effect 
of ventricular pacing on LV function in patients without rel-
evant dyssynchrony, comparable with that of a pacer-medi-
ated cardiomyopathy. In contrast, this phenomenon seems 
less pronounced in longer QRS durations (ie, >150 ms), after 
which the relative benefit of male and female patients seems 
more similar.7,8 In our subgroup analysis, male patients had 
larger LV diameters, longer QRS duration, and more fre-
quently had ischemic cardiomyopathy, previous myocar-
dial infarction and previous CABG. Although patients with 
previous myocardial infarction are generally less likely to 
respond to CRT20 or become super-responders,21 ischemic 
cardiomyopathy itself has not consistently been associated 
with a worse outcome in terms of hard end points in any 
of the major randomized clinical trials.1,22,23 The sex pattern 
observed on univariable analysis was still evident after mul-
tivariable adjustment, indicating an effect independent of, or 
at least in addition to those parameters.
In spite of the increasing evidence of a similar, if not more 
pronounced benefit of CRT in women, CRT remains largely 
underused in female compared with male patients. In absolute 
terms, women constitute a large proportion of the population 
with CHF.11,24 This is in sharp contrast to the proportion of 
women included in CRT trials (including EchoCRT), ranging 
from 17.2% (RAFT) to 32% (COMPANION).2,3,6 Similarly, 
CRT remains underused in daily clinical practice, as shown 
by only 27% females implanted in the EuroCRT survey.25 
Our current analysis cannot readily supply an answer to this 
phenomenon. A larger concern for complications after device 
implantation, both from female patients as well as from the 
referring/implanting physician has been suggested, probably 
because of smaller vessel diameter and body size.11,26 In our 
analysis, the system-/implantation-related complication rate 
was similar for men when compared with women, indicating 
that this factor per se should not discourage CRT implants 
in women.
Limitations
Although prespecified, this subgroup analysis of EchoCRT 
should by definition be interpreted as hypothesis generating, 
Table 3. CRT System–Related Serious Adverse Events During the Whole Trial
Female Patients Male Patients
P IntCRT=ON (n=110) CRT=OFF (n=114) CRT=ON (n=294) CRT=OFF (n=291)
N N Pts (%) N N Pts (%) N N Pts (%) N N Pts (%)
CRT system related 26 19 (17.27) 7 7 (6.14) 48  36 (12.24) 25 22 (7.56) 0.25
  ICD lead 10 9 (8.18) 2 2 (1.75) 16 14 (4.76) 11 11 (3.78) 0.13
  RA pacing lead 7 5 (4.55) 1 1 (0.88) 14 13 (4.42) 4 4 (1.37) 0.70
  LV pacing lead 7 6 (5.45) 2 2 (1.75) 14 12 (4.08) 2 2 (0.69) 0.57
Implantation related 6 6 (5.45) 3 3 (2.63) 13 11 (3.74) 15 13 (4.47) 0.26
CRT indicates cardiac resynchronization therapy; ICD, implantable cardioverter–defibrillator; LV, left ventricle; N, number of events; N Pts, number of 
patients with events; and RA, right atrial.
Table 2. Primary Safety End Point in Female and Male 
Patients (Complication-Free Rate Within 6 Months of 
Implantation)
Female Patients (%) 
Complication-Free  
(n total=237, %)
Male Patients (%) 
Complication-Free 
(n Total=618, %)
P Int
CRT-D system 216 (91.14) 569 (92.07) 0.66
Implant 
procedure
232 (97.89) 605 (97.90) 1
Other 236 (99.58) 617 (99.84) 0.50
Any of the above 210 (88.61) 556 (89.97) 0.56
CRT indicates cardiac resynchronization therapy.
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especially because the trial did not meet its primary end point. 
Sex was not a stratification factor at trial entry leaving the pos-
sibility of unmeasured residual confounding. Moreover, the 
trial was prematurely terminated, further reducing the statisti-
cal power of any subgroup analysis. Although the proportion 
of women included in EchoCRT is in line with other contem-
porary CRT trials, inclusion of a higher number of women may 
have increased statistical power for this subgroup analysis.
Conclusions
In the present prespecified subgroup analysis of EchoCRT, a 
trend indicating a worse outcome for males compared with 
females can be observed with CRT-ON versus CRT-OFF. This 
did not reach statistical significance, probably because of lack 
of power resulting from the premature termination of the trial. 
These data extend findings from previous large randomized 
trials and support the use of CRT in female patients if indi-
cated according to the current guidelines. Importantly, these 
data serve as a reminder to use caution with CRT implantation 
in men with a narrow QRS complex irrespective of the pres-
ence of mechanical dyssynchrony.
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